association
Full identifier: http://purl.org/np/RAurRGprOmIn3BXD75K8KSs99zq2r-R2a4lD1oRqCJxq0#association
Assigned to 1 class:
Minted in Nanopublication
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAurRGprOm...#association
This association
http://www.w3.org/2000/01/rdf-schema#label
has label
(this is a literal)
"moxifloxacin hydrochloride is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria in the conditions listed below community acquired pneumonia 1 1 skin and skin structure infections uncomplicated 1 2 1 3 complicated intra abdominal infections 1 4 plague 1 5 acute bacterial sinusitis 1 6 acute bacterial exacerbation of chronic bronchitis 1 7 to reduce the development of drug resistant bacteria and maintain the effectiveness of moxifloxacin hydrochloride and other antibacterial drugs moxifloxacin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria 1 8 moxifloxacin hydrochloride is indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis staphylococcus aureus klebsiella pneumoniae mycoplasma pneumoniae chlamydophila pneumoniae see clinical studies 14 3 mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs penicillin minimum inhibitory concentrations mic 2 mcg ml 2nd generation cephalosporins for example cefuroxime macrolides tetracyclines and trimethoprim sulfamethoxazole moxifloxacin hydrochloride is indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin susceptible staphylococcus aureus streptococcus pyogenes see clinical studies 14 4 moxifloxacin hydrochloride is indicated in adult patients for the treatment of complicated skin and skin structure infections caused by susceptible isolates of methicillin susceptible staphylococcus aureus escherichia coli klebsiella pneumoniae enterobacter cloacae see clinical studies 14 5 moxifloxacin hydrochloride is indicated in adult patients for the treatment of complicated intra abdominal infections ciai including polymicrobial infections such as abscess caused by susceptible isolates of escherichia coli bacteroides fragilis streptococcus anginosus streptococcus constellatus enterococcus faecalis proteus mirabilis clostridium perfringens bacteroides thetaiotaomicron peptostreptococcus see clinical studies 14 6 moxifloxacin hydrochloride is indicated in adult patients for the treatment of plague including pneumonic and septicemic plague due to susceptible isolates of yersinia pestis see clinical studies 14 7 moxifloxacin hydrochloride is indicated in adult patients 18 years of age and older for the treatment of acute bacterial sinusitis abs caused by susceptible isolates of or moxifloxacin hydrochloride is indicated in adult patients 18 years of age and older for the treatment of acute bacterial sinusitis abs caused by susceptible isolates of streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis see clinical studies 14 1 because fluoroquinolones including moxifloxacin hydrochloride have been associated with serious adverse reactions see warnings and precautions 5 moxifloxacin hydrochloride is indicated in adult patients for the treatment of acute bacterial exacerbation of chronic bronchitis abecb caused by susceptible isolates of methicillin susceptible or moxifloxacin hydrochloride is indicated in adult patients for the treatment of acute bacterial exacerbation of chronic bronchitis abecb caused by susceptible isolates of streptococcus pneumoniae haemophilus influenzae haemophilus parainfluenzae klebsiella pneumoniae staphylococcus aureus moraxella catarrhalis see clinical studies 14 2 because fluoroquinolones including moxifloxacin hydrochloride have been associated with serious adverse reactions see warnings and precautions 5 1 5 13 and for some patients abecb is self limiting reserve moxifloxacin hydrochloride for treatment of abecb in patients who have no alternative treatment options to reduce the development of drug resistant bacteria and maintain the effectiveness of moxifloxacin hydrochloride and other antibacterial drugs moxifloxacin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy"
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAurRGprOm...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
has drug
https://identifiers.org/drugbank:DB00218
drugbank:DB00218
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAurRGprOm...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
has disease
http://purl.obolibrary.org/obo/DOID_3481
DOID_3481
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAurRGprOm...#association
This association
https://w3id.org/biolink/vocab/relation
has relation
https://schema.org/TreatmentIndication
An indication for treating an underlying condition.
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAurRGprOm...#association
This association
https://w3id.org/biolink/vocab/association_type
has BioLink type
https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation
ChemicalToDiseaseOrPhenotypicFeatureAssociation
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAurRGprOm...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
has type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
association Statement
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAurRGprOm...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
has predicate
https://w3id.org/biolink/vocab/treats
treats
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAurRGprOm...#association
This association
https://w3id.org/biolink/vocab/provided_by
is provided by
https://w3id.org/um/NeuroDKG
NeuroDKG
.
This is the identifier for the assertion of this nanopublication.
http://purl.org/np/RAurRGprOm...#assertion
The assertion above
http://www.w3.org/ns/prov#wasAttributedTo
is attributed to
https://orcid.org/0000-0002-1468-3557
me (Leoni Bücken)
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAurRGprOm...
This nanopublication
http://purl.org/dc/terms/creator
is created by
https://orcid.org/0000-0002-1468-3557
me (Leoni Bücken)
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAurRGprOm...
This nanopublication
date and time when the nanopublication was created
http://purl.org/dc/terms/created
was created on
(this is a literal)
"2021-06-12T13:05:05.609+02:00"
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAurRGprOm...
This nanopublication
links to the assertion template that was used to create this nanopublication
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
was created from the assertion template
http://purl.org/np/RAManV5GZI...
RAManV5GZI
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAurRGprOm...
This nanopublication
links to the provenance template that was used to create this nanopublication
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
was created from the provenance template
http://purl.org/np/RANwQa4ICW...
RANwQa4ICW
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAurRGprOm...
This nanopublication
links to the publication info template that was used to create this nanopublication
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
was created from the publication info template
http://purl.org/np/RAA2MfqdBC...
RAA2MfqdBC
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAurRGprOm...#sig
sig
http://purl.org/nanopub/x/hasSignatureTarget
has as target
This is the identifier for this whole nanopublication.
http://purl.org/np/RAurRGprOm...
this nanopublication
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAurRGprOm...#sig
sig
http://purl.org/nanopub/x/hasAlgorithm
has the algorithm
(this is a literal)
"RSA"
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAurRGprOm...#sig
sig
http://purl.org/nanopub/x/hasPublicKey
has the public key
(this is a literal)
"MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAurRGprOm...#sig
sig
http://purl.org/nanopub/x/hasSignature
has the signature
(this is a literal)
"TTBDBADEs88SSnIcjzn4O1448+bTc11I+CKKVgkdVSYKuo/gc4OSzZ62aifgH0t3ctymHOp5uLIN015/g+GTeGjfRx4YT1/MhaOMQq0l5x5Sz5ZcWzCVbwS/xEtQWJyzDzLFADEl2HavRO/kb1JNNnqIhEK7KToj5O0QWSJ9mBw="
.
References
Nanopublication | Part | Subject | Predicate | Object | Published By | Published On |
---|---|---|---|---|---|---|
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-06-12T11:05:05.609Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
moxifloxacin hydrochloride is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria in the conditions listed below community acquired pneumonia 1 1 skin and skin structure infections uncomplicated 1 2 1 3 complicated intra abdominal infections 1 4 plague 1 5 acute bacterial sinusitis 1 6 acute bacterial exacerbation of chronic bronchitis 1 7 to reduce the development of drug resistant bacteria and maintain the effectiveness of moxifloxacin hydrochloride and other antibacterial drugs moxifloxacin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria 1 8 moxifloxacin hydrochloride is indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis staphylococcus aureus klebsiella pneumoniae mycoplasma pneumoniae chlamydophila pneumoniae see clinical studies 14 3 mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs penicillin minimum inhibitory concentrations mic 2 mcg ml 2nd generation cephalosporins for example cefuroxime macrolides tetracyclines and trimethoprim sulfamethoxazole moxifloxacin hydrochloride is indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin susceptible staphylococcus aureus streptococcus pyogenes see clinical studies 14 4 moxifloxacin hydrochloride is indicated in adult patients for the treatment of complicated skin and skin structure infections caused by susceptible isolates of methicillin susceptible staphylococcus aureus escherichia coli klebsiella pneumoniae enterobacter cloacae see clinical studies 14 5 moxifloxacin hydrochloride is indicated in adult patients for the treatment of complicated intra abdominal infections ciai including polymicrobial infections such as abscess caused by susceptible isolates of escherichia coli bacteroides fragilis streptococcus anginosus streptococcus constellatus enterococcus faecalis proteus mirabilis clostridium perfringens bacteroides thetaiotaomicron peptostreptococcus see clinical studies 14 6 moxifloxacin hydrochloride is indicated in adult patients for the treatment of plague including pneumonic and septicemic plague due to susceptible isolates of yersinia pestis see clinical studies 14 7 moxifloxacin hydrochloride is indicated in adult patients 18 years of age and older for the treatment of acute bacterial sinusitis abs caused by susceptible isolates of or moxifloxacin hydrochloride is indicated in adult patients 18 years of age and older for the treatment of acute bacterial sinusitis abs caused by susceptible isolates of streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis see clinical studies 14 1 because fluoroquinolones including moxifloxacin hydrochloride have been associated with serious adverse reactions see warnings and precautions 5 moxifloxacin hydrochloride is indicated in adult patients for the treatment of acute bacterial exacerbation of chronic bronchitis abecb caused by susceptible isolates of methicillin susceptible or moxifloxacin hydrochloride is indicated in adult patients for the treatment of acute bacterial exacerbation of chronic bronchitis abecb caused by susceptible isolates of streptococcus pneumoniae haemophilus influenzae haemophilus parainfluenzae klebsiella pneumoniae staphylococcus aureus moraxella catarrhalis see clinical studies 14 2 because fluoroquinolones including moxifloxacin hydrochloride have been associated with serious adverse reactions see warnings and precautions 5 1 5 13 and for some patients abecb is self limiting reserve moxifloxacin hydrochloride for treatment of abecb in patients who have no alternative treatment options to reduce the development of drug resistant bacteria and maintain the effectiveness of moxifloxacin hydrochloride and other antibacterial drugs moxifloxacin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy
|
Leoni Bücken
|
2021-06-12T11:05:05.609Z
|
||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-06-12T11:05:05.609Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-06-12T11:05:05.609Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-06-12T11:05:05.609Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-06-12T11:05:05.609Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-06-12T11:05:05.609Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-06-12T11:05:05.609Z
|